Uncategorized
Analysts Turn Cautious On Crocs After Underwhelming Guidance
Crocs beat Q2 earnings expectations but lowered Q3 guidance as analysts cut price targets amid macro pressure and a softer North America outlook. Latest Ratings for CROX Date Firm Action From To Feb 2022 Loop Capital Maintains Buy Jan 2022 B. Riley Securities Maintains Buy Jan 2022 Seaport Global Initiates Coverage On Neutral View More…
Money Supply Is Under Control, Until De-dollarized Capital Comes Home To Roost
U.S. dollar-denominated money supply grew 3.87% in Q2 2025, while the Dollar Index dropped 7.03%, amplifying the rise in global M2. Domestic M2 hit a record $22 trillion, with a year-over-year growth of 4.5%. However, factors like slower velocity of money and tariffs could prevent inflation. read more
Why Ouster (OUST) Stock Is Soaring On Its ‘Physical AI’ Strategy And Q2 Results
Ouster stock is surging Friday afternoon. The lidar technology company reported impressive financial results for Q2. read more
Tech Stocks Eye Record Highs As Magnificent Seven Top $19.5 Trillion: What’s Moving Markets Friday?
Tech stocks staged a full rebound from last Friday’s sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and broad gains among the Magnificent Seven fueled the rally. read more
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. read more